Related Experiment Video
Updated: Jul 1, 2026

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
Published on: January 26, 2024
Mechanical regulation of adipogenic reprogramming suppresses ovarian cancer progression
Yu-Huan Li1, Jia-Wen Zhao1,2,3, Xin Wang2,3,4
1Maternity Center, First Hospital of Jilin University, Changchun, Jilin, China.
Abstract:
Epithelial ovarian cancer (EOC) is a lethal malignancy with high recurrence rates owing to residual micrometastases and chemoresistance. This study explores cytoskeletal regulation as a potential therapeutic strategy to modulate tumor cell fate. We demonstrate that combining (‒)-Blebbistatin (Ble) with adipogenic stimuli (BMP4 or PPARγ agonists) effectively induces adipogenic transdifferentiation of ovarian cancer cells both in vitro and in vivo. The transformed cells exhibit characteristic lipid droplet accumulation, upregulated adipogenic markers (PPARG, CEBPA, and FABP4), and functional maturation evidenced by β-adrenergic-responsive lipolysis. In subcutaneous and intraperitoneal models, Ble treatment significantly suppressed tumor growth, with HuNu/Perilipin 1 colocalization confirming human tumor cell conversion into adipocyte-like cells. Mechanistic investigations reveal that cytoskeletal destabilization triggers nuclear heterochromatin redistribution and chromatin decondensation, enhancing accessibility for adipogenic transcription factors (CEBPA and CEBPB) to activate related transcriptional programs. The critical role of mechanical signaling is demonstrated by both adipogenic conversion on soft substrates and the prevention of Ble-triggered adipogenesis following overexpression of a constitutive nuclear localization mutant of YAP. These findings establish that cytoskeletal destabilization in combination with adipogenic instructive cues enable the adipogenic reprogramming of EOC cells via heterochromatin remodeling, providing preclinical insights for ovarian cancer differentiation-targeted therapy.
Insights
Reprogramming ovarian cancer cells into adipocytes using (‒)-Blebbistatin and adipogenic stimuli halts tumor growth. This cytoskeletal destabilization approach offers a novel differentiation-targeted therapy for epithelial ovarian cancer (EOC).
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Epithelial ovarian cancer (EOC) is a deadly malignancy with frequent recurrence due to chemoresistance and micrometastases.
- Cytoskeletal regulation is explored as a novel therapeutic strategy to alter cancer cell fate.
Purpose of the Study:
- To investigate the potential of combining cytoskeletal destabilization with adipogenic stimuli to induce transdifferentiation of EOC cells.
- To elucidate the underlying mechanisms of this reprogramming and its therapeutic implications.
Main Methods:
- Ovarian cancer cells were treated with (‒)-Blebbistatin (Ble) and adipogenic stimuli (BMP4 or PPARγ agonists) in vitro and in vivo.
- Tumor growth suppression was assessed in subcutaneous and intraperitoneal models.
- Mechanistic studies involved analyzing lipid droplet accumulation, adipogenic marker expression, chromatin remodeling, and mechanical signaling pathways (YAP).
Main Results:
- The combination treatment effectively induced adipogenic transdifferentiation of EOC cells, characterized by lipid accumulation and upregulated adipogenic markers.
- Transformed cells exhibited functional lipolysis and tumor growth suppression in preclinical models.
- Cytoskeletal destabilization was shown to trigger heterochromatin redistribution, enhancing transcription factor accessibility and promoting adipogenesis, with YAP signaling playing a critical role.
Conclusions:
- Cytoskeletal destabilization combined with adipogenic cues can reprogram EOC cells into adipocyte-like cells via heterochromatin remodeling.
- This differentiation-targeted approach shows promise for overcoming EOC recurrence and chemoresistance.
- The findings provide preclinical evidence for a novel therapeutic strategy in ovarian cancer treatment.
More Related Videos
Related Concept Videos
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Regulation of Food Intake

